Non-arrhythmogenic metabolite of oxybutynin
AssigneeBridge Pharma, Inc.
InventorA.K. Gunnar Aberg
Life of this patent
Estimating the term…
Abstract
A method of treating disorders involving the urethrogentical tract by administering to pateints in need thereof therapeutically effective amounts of the desethyl metabolite of oxybutynin and/or the optically active isomers thereof, which are free from said cardiac side effect of oxybutynin, while maintaining the therapeutic activities of oxybutynin or the optically active isomers thereof.
Claims8
A method for treating or preventing disorders involving the urethrogenital tract, which method comprises administering to a mammal in need of such treatment a therapeutically effective amount of 4-ethylamino-2-butynyl cyclohexyl-phenylglycolate and/or one or more optically active isomers thereof, and pharmaceutically acceptable salts thereof.
Dependencies are inferred from the claim text.